Abbvie takes over Novo Holdings portfolio company Syndesi Therapeutics has been acquired by Abbvie in a USD 1bn deal. Photo: PR / Novo Seeds by victor emil kristensen, translated by catherine brett Published: 02.03.22 at 07:44 After four years of ownership, Novo Holdings has decided to sell Belgian portfolio company Syndesi Therapeutics to Abbvie. The deal may total up to USD 1bn, with a USD 130m upfront payment. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch Zealand Pharma sells shares for over USD 100m With a 5% discount, the biotech company managed to sell 4,975,000 of its own shares in a direct issuance. Zealand Pharma CEO: Share sale arms us for partnership negotiations After a study success with short bowel syndrome treatment candidate, the Danish biotech company raised funding by issuing shares, preparing the company’s CEO, Adam Steensberg, to enter dialogs with a number of potential partners. Complete company divestment is not part of Zealand Pharma's strategy After a Nordnet analyst brought up the possibility of the Danish company being an acquisition target for foreign firms, CEO Adam Steensberg has ruled out the notion of a full sale. Three scientists share chemistry Nobel for cancer improvement technology breakthrough Danish national Morten Meldal and two colleagues have been awarded the prestigious award for their research into click chemistry, which is used the development of cancer drugs. Audientes builds on Q2 momentum, maintains guidance The hearing aid company has sold self-fitting hearing aids for over DKK 2m (USD 266,700) during the third quarter that ended in September. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading Former Ambu employee stands trial for alleged insider trading Zealand Pharma sells shares for over USD 100m Novo Nordisk faces potential impact of new US legislation Novo Nordisk's Rybelsus hasn't lived up to expectations, say analysts Analyst deems Novo Nordisk once-weekly insulin has blockbuster potential Related articles Finnish investor looks for Nordic investors in its new life science & health fund Novo Holdings acquisition highlights growing pharma commercialization service market, says managing partner Biotech boss overjoyed by new life science fund: "The more the merrier"